MAPT and Alzheimer disease: Various phosphorylated tau (pTau) isoforms, such as pTau181, pTau217, and pTau231, appear thus far to be among the most promising AD biomarkers in plasma (3–7) and have shown promise in predicting progression from MCI to AD dementia in individual patients (6, 8–10).